|Videos|March 24, 2023
Role of Multidisciplinary Care and Early BCC Identification
Author(s)John Strasswimmer, MD, PhD
An expert in the management of basal cell carcinoma stresses the importance of early identification and engaging a multidisciplinary team in the management of patients suffering from this condition.
Advertisement
Episodes in this series
Advertisement
Related to this article
Shannon Trotter, DO, moderated a Dermatology Times Case-Based Roundtable event on how pharmacokinetics, adverse event timing, and trial response criteria should shape hedgehog pathway inhibitor selection in advanced BCC.
Cosibelimab-ipdl is now an NCCN Category 2A option for locally advanced CSCC in patients ineligible for curative surgery or radiation.
Advertisement
Advertisement
Trending on Dermatology Times
1
Clinicians Debate JAK Inhibitor Selection in Alopecia Areata
2
Menopause and the Skin: Recognizing Changes Beyond Aging
3
Lutikizumab Meets Primary End Point in Phase 3 HS Trial
4
Social Media Mythbusters: Can Face Taping Really Prevent Wrinkles?
5